COVID-19 is frequently associated with a wide spectrum of neurological dysfunction that can persist long after the acute infection. Remsik et al. analysed cerebrospinal fluid from patients with cancer who had neurological manifestations after SARS-CoV-2 infection. They found an increase in intracranial inflammatory mediators such as IL-6, IL-8, IFNγ and MMP10, in the absence of viral neuroinvasion. IFNγ and its downstream effectors CXCL9, CXCL10 and CXCL11 were still elevated nearly 2 months after the infection and intracranial levels of MMP10 correlated with the degree of neurological dysfunction. These findings support the investigation of anti-inflammatory drugs to treat neurological symptoms following COVID-19.
References
Original article
Remsik, J. et al. Inflammatory leptomeningeal cytokines mediate COVID-19 neurologic symptoms in cancer patients. Cancer Cell https://doi.org/10.1016/j.ccell.2021.01.007 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flemming, A. Intracranial inflammatory mediators involved in SARS-CoV-2 neurological manifestations?. Nat Rev Immunol 21, 136 (2021). https://doi.org/10.1038/s41577-021-00512-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-021-00512-3
